Equivalence of plasma and serum for clinical measurement of p-tau217: comparative analyses of four blood-based assays

Yijun Chen[1,2], Ally L. Albert[1], Anuradha Sehrawat[1], Marissa Farinas[1], Oscar L. Lopez[1,3], Xuemei Zeng[1], Ann D. Cohen[1], Thomas K. Karikari[1#]

[1]Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA

[2]Department of Chemistry, University of Pittsburgh, Pittsburgh, PA 15213, USA

[3]Department of Neurology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213 USA

[#]Corresponding author: Thomas K. Karikari, Biofluid Biomarker Laboratory, Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. 3811 O'Hara St., Pittsburgh, PA, 15213, USA. Karikaritk@upmc.edu

Abstract

Background: Phosphorylated tau (p-tau) 217 has emerged as a promising blood biomarker for Alzheimer's disease (AD). However, most p-tau217 assays have been validated solely in ethylenediaminetetraacetic acid (EDTA) plasma, leaving the clinical applicability of serum p-tau217 largely unexplored despite serum being the preferred matrix in many clinical laboratories. To address this gap, we compared p-tau217 concentrations and diagnostic performance of p-tau217 in matched plasma and serum samples using four research-use-only assays, including three from commercial sources i.e., Lumipulse, ALZpath, NULISA, and one from University of Pittsburgh.

Methods: Paired plasma and serum samples were processed from the same venipuncture collection and assessed with the four p-tau217 assays following manufacturer-recommended procedures in two research cohorts (N=84).

Results: Plasma and serum p-tau217 levels varied across assays; the ALZpath, Pittsburgh, and NULISA methods showed significantly lower p-tau217 levels in serum compared with plasma (p<0.0001), while Lumipulse showed higher or non-significant differences in serum. Yet, strong correlations (rho >0.8) were observed between plasma and serum p-tau217 pairs. Both plasma and serum p-tau217 demonstrated strong classification accuracies to differentiate clinical AD from normal controls, with high area under the curve (AUC) values (up to 0.963) for all methods. The exception was the Pittsburgh assay, where plasma p-tau217 had superior AUC than serum p-tau217 (plasma: 0.912, serum: 0.844). The rest of the assays had equivalent accuracies in both matrices.

Conclusions: Serum p-tau217 performs equivalently as plasma p-tau217 for most assays. Serum can therefore be used in place of plasma for p-tau217 assessment for research and clinical purposes.

Keywords: Alzheimer's disease, p-tau217, biomarker, serum, plasma, ALZpath p-tau217, Lumipulse p-tau217, NULISA p-tau217, Pittsburgh p-tau217.

Introduction

Biomarkers are integral to the diagnosis, treatment, and research of Alzheimer's disease (AD). Currently, positron emission tomography (PET) neuroimaging and cerebrospinal fluid (CSF) biomarker measurements are clinically approved methods for antemortem AD diagnosis. [1, 2] Although PET imaging and CSF assays are critical tools in AD research and clinical care, their invasiveness, high costs, and limited availability significantly restrict applications in routine clinical practice and population screening. [3] In contrast, blood-based biomarker assays offer cost-effective and minimally invasive alternatives with the potential to address the aforementioned limitations, thereby enhancing the accessibility and widespread availability of AD diagnostics. [4, 5]

Among the available blood biomarkers, phosphorylated tau217 (p-tau217) is considered one of the most promising indicators of AD pathology. It is prominently featured in the latest diagnostic and research guidelines, including the 2024 Alzheimer's Association revised criteria [6] and the 2024 International Working Group recommendations. [7] Blood p-tau217 can effectively identify individuals with biological evidence of AD even at the preclinical stages, and robustly distinguish AD from other neurodegenerative disorders with high accuracy. [8-13] Additionally, plasma p-tau217 levels initially rise with amyloid-beta (Aβ) plaque accumulation in the brain and later increase with tau tangle abnormalities in AD, allowing for early detection and ongoing monitoring as the disease progresses. [14, 15]

Multiple academic groups and companies have developed plasma-based p-tau217 assays that can be classified under two main techniques: immunoassays and mass spectrometry, with most assays currently available being the former (for a review, see [16]). These p-tau217 assays have been mainly tested in ethylenediaminetetraacetic acid (EDTA) plasma (hereafter referred to as plasma). However, clinical laboratories in many hospital systems preferentially collect serum over plasma. [17] Despite this preference, the utility and clinical applicability of serum p-tau217 remain largely unexplored. Assessing p-tau217 in serum is essential to guide its adoption in such clinical settings, particularly for enhancing early AD detection and timely intervention.

We compared levels of p-tau217 and their predictive performances for Aβ pathology and cognitive status using matched plasma and serum samples from two distinct cohorts, utilizing four research-use-only p-tau217 assays: three from commercial sources (Lumipulse from

Fujirebio, ALZpath from Quanterix and the Nucleic acid linked immuno-sandwich assay (NULISA) from Alamar Biosciences) and the fourth from an academic laboratory (University of Pittsburgh).

Materials and Methods

2.1 Participant recruitment

This study included participants from two distinct cohorts. The first cohort was recruited through the University of Pittsburgh Alzheimer's Disease Research Center (Pitt-ADRC). The participants underwent annual clinical evaluations, including neuropsychological assessments, to monitor brain health and detect signs or progression of cognitive decline. [18, 19] Neuroimaging, performed separately from routine clinical assessments, was not available for the present study. Neuropsychological testing involved a range of cognitive tests, such as the Montreal Cognitive Assessment (MoCA), Mini-Mental State Examination (MMSE), and the Clinical Dementia Rating (CDR). The present investigation was a prospective, blinded sub-study of the Pitt-ADRC cohort. Participants were selected based on willingness to provide informed consent, which included authorization for an additional blood draw specifically for this sub-study. The ADRC study was reviewed and approved by the University of Pittsburgh Institutional Review Board (MOD19110245-023).

The second cohort was from the Human Connectome Project (HCP) study. Participants were recruited through the Pitt-ADRC and the Pitt + Me web portal. Upon their enrollment, participants were subjected to a detailed battery of cognitive tests such as the MoCA, tests of verbal fluency, visual naming, Trail Making Test, verbal free recall, and the Rey-Osterrieth Complex Figure Test to evaluate their cognitive function. The imaging methodologies incorporated in this study included structural and functional magnetic resonance imaging (MRI), diffusion tensor imaging, and PET imaging with Pittsburgh Compound B (PiB) to ascertain Aβ deposits in the brain. These evaluations were conducted over a span of three days, initiating with MRI and cognitive assessments, followed by fasting blood tests and additional imaging sessions, including the PiB PET scans. [20] The HCP study was approved by the University of Pittsburgh Institutional Review Board (STUDY19100015C). All participants provided written

informed consent, in compliance with the ethical standards and protocols sanctioned by the university's Human Research Protection Office.

2.2 Blood collection and processing procedures

Blood samples were collected via venipuncture by nurses with extensive clinical experience and trained in Pitt-ADRC procedures [21], between 9:00 am and 2:00 pm with the time of last meal recorded. Similar approaches were followed for the HCP cohort, using the same biobanking procedures. [21]

For the blood collection, a 10 ml Lavender top EDTA plasma tube (BD #366643) and a 10 ml red top serum tube (BD #368045) were used to collect whole blood from each participant. Following each blood draw, the tubes were promptly inverted 8 to 10 times (EDTA tube) and 5 times (serum tube). After inversions, tubes were left at room temperature for 30 minutes and centrifuged at 2000 xg for 10 minutes at 4°C. The resulting plasma and serum samples were aliquoted into cryovials and frozen at -80°C until use.

2.3 P-tau217 measurements

Before biomarker analysis, the plasma and serum samples were thawed, vortexed, and centrifuged at 4,000 x g for 10 minutes to remove particulates. The clarified supernatants were then analyzed using various assays. Identical reagent batches were used for plasma and serum samples within each assay. All samples were measured in duplicates except for NULISA. All measurements were conducted at the Biofluid Biomarker Laboratory, Department of Psychiatry, School of Medicine, University of Pittsburgh, PA, USA. Researchers were blinded to all participant information until the completion of data acquisition.

ALZpath p-tau217

The commercial ALZpath-p-tau217 kit (Quanterix, #104570) was used on the Single molecule array (Simoa) HD-X platform, following the manufacturer's protocols. Three levels of Quality control (QC) samples were analyzed in duplicate at both the beginning and the end of each run. The within- and between-run variations for the three QCs ranged between 2.0%-6.5% and 5.8%-9.7%, respectively, for the ADRC cohort and 1.5%-11.5% and 7.6%-17.0% for the HCP cohort. One serum sample failed in the HCP cohort and was excluded from further analysis.

Pittsburgh p-tau217

The Pittsburgh assay, developed at the University of Pittsburgh on the Simoa HD-X platform, employs a monoclonal antibody specific to p-tau217, coupled to paramagnetic beads (#103207, Quanterix), for capturing the antigen, and a biotin-conjugated mouse monoclonal antibody against the N-terminal region of tau (Tau12; BioLegend, #SIG-39416) for detection. [22, 23] In vitro phosphorylated recombinant full-length tau-441 (T08-50FN-50, SignalChem) was used as the calibrator. Samples and calibrators were diluted threefold to position the assay signals around the mid-point of the standard curve. For each run, two levels of QC samples were analyzed in duplicates at the start and end of each run. The within- and between-run variations were 7.1-7.8% and 11.6-17.5% for ADRC and HCP cohorts, respectively. One serum sample failed in the HCP cohort and was excluded from further analysis.

Lumipulse p-tau217

Lumipulse p-tau217 assay was conducted on the Lumipulse G1200, a fully automated platform, following the manufacturer's guidelines. We utilized commercially sourced kits (#81471) from Fujirebio Europe (Ghent, Belgium) specifically designed for the quantitative measurement of p-tau217 in human blood. The QC samples were conducted in accordance with the manufacturer's guidelines. Two levels of QCs were used to monitor assay performance at both the beginning and end of each batch. Both measured QC concentrations fell within the acceptable concentration ranges provided by the manufacturer.

NULISA assay

For NULISA, samples were analyzed using the NULISAseq CNS disease panel 120 (v2) on an Alamar ARGO^{TM} system, as previously described. [11][24] Briefly, samples were incubated with paired capture and detection antibodies, with mCherry protein as an internal control. Capture antibodies were conjugated to DNA with a poly-A tail and target-specific barcode, while detection antibodies were conjugated to DNA containing a biotin group and complementary barcode. Immunocomplexes were captured on magnetic beads, washed, and released, then recaptured using streptavidin-coated beads. Target- and sample-specific barcoded DNA reporters were synthesized via ligation and quantified using next-generation sequencing. Protein levels were normalized to generate NULISA Protein Quantification (NPQ) units by dividing target counts (plus one) by mCherry counts (plus one). The initial NPQ values were log2 transformed. To make the data more intuitive, we then applied an inverse log2 transformation (2^NPQ) for the analysis. All samples were analyzed in a single run. QC samples

were processed following the manufacturer's guidelines, achieving an intra-plate variation of 18.23%. We focused on p-tau217 data in this study, leaving out the other analytes.

2.4 Statistical analysis

For participant demographic characteristics, continuous variables were summarized using median and interquartile range (IQR), while categorical variables were reported as numbers and percentages. Differences between clinical/Aβ PET groups for continuous variables were examined using the Wilcoxon Rank Sum test. Categorical variables were analyzed using Fisher's exact tests. The Wilcoxon Rank Sum test was also used to assess the discriminating performance of biomarkers on cognitive status for the Pitt-ADRC cohort. Due to the small sample size of the Aβ PET-positive cases in the HCP cohort (only three cases), no comparative statistical test was performed. Spearman correlation analysis was conducted to evaluate the strength of associations among different assay platforms and between plasma and serum. The Delong test was used to compare the receiver operating characteristic (ROC) curve difference between the plasma and the corresponding serum assays. For all tests, a p-value less than 0.05 was considered statistically significant. Analyses were performed using the R statistical software (version 4.2.1, R Foundation for Statistical Computing, Vienna, Austria). Plots were generated either with R or GraphPad Prism (version 10.1.1).

Results

Participant characteristics

In the Pitt-ADRC cohort (n=50), the median age was 76 (70.3- 82.0) years, with 21 (42.0%) females. Sixteen (32.0%) were diagnosed with probable AD and thirty-four (68.0%) as normal controls. In terms of cognitive performance, the median MMSE and MoCA scores were 27.0 (23.0- 29.0) and 23.0 (16.5- 27.0), respectively. Sixteen participants (32.0%) had a CDR score of "disease absent" (CDR=0), 24 (48.0%) were scored as "questionable" (CDR=0.5), and 5 (10.0%) each as "disease present but mild" (CDR=1), and "moderate" (CDR=2). There were significant differences in MoCA, MMSE and CDR scores between the probable AD and the normal control groups. (Table 1)

Due to biospecimen limitations, we included a slightly smaller Pitt-ADRC cohort for the NULISA assay (n=43, instead of 50). The median age was 76 (70.0-81.5) years, with 18 (41.9%) females. Fourteen (32.6%) were diagnosed with probable AD and twenty-nine (69.4%) as normal controls. Cognitively, the median MMSE and MoCA scores were 27.0 (23.0- 29.0) and 25.0 (17.0- 28.0), respectively. Regarding CDR scores, 15 participants (34.9%) were CDR=0, 19 (44.2%) had CDR=0.5, 4 (9.3%) were CDR=1, and 5 (11.6%) had CDR=2. Comparing these metrics between the probable AD and normal control groups indicated significant differences in MoCA, MMSE and CDR scores. (Table 1)

In the HCP cohort (n=34), the median age was 65 (62.3-74.0) years, with 24 (70.6%) females. Three (8.8%) were Aβ-PET positive and thirty-one (91.2%) were Aβ-PET negative. The median MoCA score was 25.5 (23.3- 27.8). Regarding self-identified race, 22 participants (68.8%) were non-Hispanic White, 9 (29.1%) were African Americans, and one (3.1%) was native American, Irish or Southern Asian. For education, 12 (35.3%) had less than eighth grade education, 5 (14.7%) had eighth to eleventh grade education, 16 (47.1%) had graduated high school or general educational development (GED) education, and 1 (2.9%) had certificate education. (Table. 1)

3.2 Precision and detectability of p-tau217 in plasma versus serum

The precision of the assays, defined as the consistency between duplicate measures, was evaluated. The ALZpath, Lumipulse, and Pittsburgh assays demonstrated slightly better precision in serum (9.4%, 7.6%, and 9.2%, respectively) compared with plasma (10.7%, 10.1%, and 11.1%, respectively). Precision for p-tau217 in the NULISA assay was not measured, as all samples were analyzed in a single run.

For detectability, the ALZpath assay had two serum samples below the low limit of quantification (LLOQ) of 0.00978 pg/mL. In contrast, all samples analyzed with the Lumipulse assay had concentrations above its LLOQ of 0.037 pg/mL. [25] For NULISA, one plasma sample and six serum samples were below the target LLOQ (2^{NPQ}=1625.52).

Together, p-tau217 exhibited slightly better precision in serum versus plasma, while detectability of ALZpath and NULISA appeared more favorable in plasma than serum.

3.3 Concentration difference between matched plasma and serum

P-tau217 concentrations (pg/mL) were compared between plasma and serum across all assays. In the Pitt-ADRC cohort, both the ALZpath (plasma = 0.47 [0.31–0.91] pg/mL vs. serum = 0.35 [0.19–0.63] pg/mL) and Pittsburgh (plasma = 25.0 [17.95–57.06] pg/mL vs. serum = 18.38 [10.61–33.90] pg/mL) assays showed significantly higher (p < 0.0001) p-tau217 levels in plasma compared with serum. Conversely, the Lumipulse assay demonstrated significantly higher (p < 0.0001) levels in serum (0.27 [0.18–0.70] pg/mL) than in plasma (0.26 [0.15–0.59] pg/mL) (Figure 1A, B). A similar trend was observed in the HCP cohort, where the ALZpath assay showed significantly higher (p < 0.0001) p-tau217 levels in plasma (0.21 [0.15–0.29] pg/mL) than in serum (0.08 [0.05–0.11] pg/mL), and the Pittsburgh assay gave 8.79 [7.33–15.26] pg/mL in plasma compared with 4.29 [2.17–10.11] pg/mL in serum. However, the Lumipulse assay showed no significant difference between plasma (0.11 [0.09–0.17] pg/mL) and serum (0.12 [0.09–0.15] pg/mL) in the HCP cohort. (Figure 2A, B)

Correlation analyses between plasma and serum p-tau217 levels in the Pitt-ADRC cohort revealed strong positive correlations. The strongest correlation was observed for the Lumipulse assay with a correlation coefficient of 0.979. (Figure 1C) The ALZpath and Pittsburgh assays also showed high correlations (r=0.915 and r=0.913, respectively). In the HCP cohort, the Lumipulse and Pittsburgh assays recorded high correlations (r=0.847 and r=0.876, respectively), while the ALZpath assay displayed a moderate correlation (r=0.508). (Figure 2C)

For NULISA, there were significantly higher (p < 0.0001) p-tau217 concentrations in plasma 3191.46 [2164.98-5367.37] 2^NPQ) than in serum (2486.67 [1728.23-3492.39] 2^NPQ). (Figure 3A, B) Correlation analysis revealed a strong positive relationship between plasma and serum measurements (r=0.902). (Figure 3C).

These results showed that p-tau217 levels were higher in plasma than matched serum for the Pittsburgh, ALZpath and NULISA assays. However, Lumipulse recorded similar/equivalent p-tau217 levels when measured in either matrix, showing matrix-based differences for the various assays.

3.4 Clinical performance of p-tau217 using different sample types across assays

The plasma and serum p-tau217 levels were evaluated for their performance in distinguishing clinically diagnosed AD status from normal controls. The ALZpath, Pittsburgh, NULISA and Lumipulse assays all had significantly higher p-tau217 concentrations for probable AD

individuals compared with normal controls across all assays (p<0.0001), whether plasma or serum was used. (Figure 4A)

The Area Under the Curve (AUC) results for p-tau217 to separate probable AD from normal controls demonstrated high performance across all methods. For Lumipulse, both plasma (AUC=0.963) and serum (AUC=0.961) p-tau217 showed similarly high accuracies. Furthermore, the ALZpath assays showed high reliability in both plasma and serum with AUCs of 0.916 and 0.899, respectively. The Pittsburgh assay achieved AUCs of 0.912 in plasma and 0.844 in serum, suggesting better performance in plasma. This was similar to NULISA with an AUC of 0.918 for plasma and 0.879 for serum. The Delong test between the corresponding plasma and serum samples indicated no difference in performance for all assays except for the Pittsburgh method (p=0.014, Supplement table 1). (Figure 5)

In the HCP cohort, p-tau217 levels in both plasma and serum were higher in the Aβ-PET positive versus Aβ-PET negative groups. However, due to the limited sample size in the Aβ-PET positive group (only 3 cases), statistical testing or AUC comparisons were not performed (Figure 4B).

The results indicated equivalent clinical performance of p-tau217 assays in plasma and serum for Lumipulse, ALZpath, and NULISA. However, the Pittsburgh assay demonstrated significantly better performance in plasma compared to serum.

3.5 Correlation between different assay platforms

In Pitt-ADRC, all assay comparisons showed significant correlations. Plasma measurements indicated strong correlations with the r-value of 0.848 for Pittsburgh vs. ALZpath, 0.915 for Lumipulse vs. ALZpath, and 0.868 for Lumipulse vs. Pittsburgh. Serum measurements displayed relatively moderate correlations, with correlation coefficients of 0.752 for Pittsburgh vs. ALZpath, 0.892 for Lumipulse vs. ALZpath, and 0.762 for Lumipulse vs. Pittsburgh. Complete correlation information is shown in Supplementary Figure 1A.

In the reduced Pitt-ADRC cohort, NULISA also showed strong correlations with the other assays. In plasma, the correlation coefficients were 0.785 against ALZpath, 0.793 against Pittsburgh, and 0.888 against Lumipulse. In serum, the correlation coefficients were 0.799 against ALZpath, 0.756 against Pittsburgh, and 0.857 against Lumipulse. (Supplementary Figure 1B)

In HCP, significant correlations were also observed across all assays. Plasma measurements demonstrated moderate to strong correlations, with correlation coefficients of 0.648 for Lumipulse vs. ALZpath, 0.828 for Pittsburgh vs. ALZpath, and 0.632 for Lumipulse vs. Pittsburgh. Serum measurements showed lower correlations, following a similar trend, with correlation coefficients of 0.357 for Lumipulse vs. ALZpath, 0.505 for Lumipulse vs. Pittsburgh, and 0.435 for Pittsburgh vs. ALZpath. (Supplementary Figure 1C)

Together, p-tau217 assays from different sources show moderate to strong correlations when measured in either plasma or serum.

Discussion

Plasma has been the primary matrix for p-tau217 measurements and has already been head-to-head compared across multiple assays. [26] Due to its broader availability in clinical practice, attributed to higher yield per unit of blood, simplified processing, and minimal use of additives, serum represents a critical alternative matrix for validating p-tau217 measurement. [17] Establishing the reliability of serum is particularly important as p-tau217 continues to gain prominence in anti-amyloid clinical trials and diagnostic applications. In this study, a direct comparison of p-tau217 levels in plasma and serum was conducted across four distinct assays: ALZpath, Pittsburgh, Lumipulse, and NULISA. This analysis not only assessed the reliability of serum as a matrix for p-tau217 detection but also investigated its ability to distinguish AD participants from normal controls. To the best of our knowledge, this is the first study to provide a systematic evaluation of p-tau217 in serum across multiple assay platforms, highlighting its potential integration into both research and clinical workflows.

Our findings revealed notable differences in p-tau217 levels between matched plasma and serum samples across most but not all assays. Specifically, p-tau217 levels were lower in serum compared to plasma when measured using the ALZpath, Pittsburgh, and NULISA assays. This may be attributed to unclear differences in assay binding characteristics and substantial variations in biomarker concentrations between serum and plasma. [27-29] Conversely, the Lumipulse assay demonstrated comparable or higher p-tau217 levels in serum relative to plasma, potentially due to differences in assay design and/or protein recovery efficiency favoring the Lumipulse p-tau217 method over others.

All p-tau217 assays examined exhibited very high clinical performance in distinguishing between probable AD and normal controls when serum in lieu of plasma was used. The AUC values in the Pitt-ADRC cohort ranged from 0.84 to 0.96, indicating strong distinguishing accuracies across assays. Statistical analyses revealed no significant differences in AUC between the plasma and corresponding serum samples for the Lumipulse, ALZpath, and NULISA p-tau217 assays, establishing a potential to use serum for these p-tau217 measurements. These results show the robust performance of serum p-tau217 assays and support its use as a feasible option in both research and clinical settings. While the clinical performance of most p-tau217 assays was comparable between serum and plasma, allowing either matrix to be used in clinical and research settings, it is crucial to avoid intermixing plasma and serum in studies, such as longitudinal analyses, due to variability in absolute concentrations between the two matrices. Thus, plasma and serum must be used independently for any given study.

We did not observe a significant difference in precision between the Lumipulse, ALZpath, and Pittsburgh assays. However, both ALZpath and NULISA recorded some serum samples that fell below the LLOQ. By extension, this suggests that more serum samples are likely to return outside the measurable zone when using these assays.

While our results show that all the evaluated platforms can be used for serum p-tau217 measurement, the platform selection must be carefully considered. The Lumipulse assay showed similar or higher levels of p-tau217 in serum relative to plasma, thereby reducing concerns of sample type-dependent detectability issues. Moreover, the Lumipulse platform, which is FDA-approved for in vitro diagnostic use for CSF Aβ and tau biomarker assays, might have potential applicability in broader biomarker contexts. Nevertheless, the Lumipulse assay requires a higher dead volume, and a higher sample volume compared with the other assays, limiting its utility in scenarios with restricted sample volume availability. In such cases, the ALZpath, Pittsburgh, or NULISA assays may be more suitable for serum p-tau217 measurement. On the other hand, the NULISA platform offers the capability to measure over 100 biomarkers simultaneously, presenting a valuable tool for comprehensive biomarker studies. However, its higher cost and inability to provide absolute quantification at its current stage may limit its suitability for clinical studies at the current time. The ALZpath and Pittsburgh assays, both utilizing the HD-X Simoa instrument, offer versatility for defined-assay workflows, making them suitable for targeted serum p-tau217 analyses.

Our findings on p-tau217 share similarities with those from a previous study on plasma p-tau181 and p-tau231, with the two biomarkers having higher absolute levels in plasma than serum but equivalent accuracies to differentiate Aβ-positive AD dementia from Aβ-negative controls. [30]

Strengths and limitations

Our study has several significant strengths. First, we included two separate cohorts – one from a memory clinic setting and the other from a racially diverse community-based research study, enhancing the generalizability and practical relevance of our findings due to their diverse representation. Moreover, while our analysis of the Pitt-ADRC cohort focused on cognitive status, our interest in the HCP cohort was aimed at brain Aβ pathology according to PiB PET imaging. Each cohort was thoroughly characterized by clinical evidence of disease through cognitive evaluations including the MMSE, MoCA, and CDR, as well as clinical assessment or brain Aβ PET imaging. Additionally, we evaluated p-tau217 using four different assays, providing a comprehensive analysis of the diagnostic utility of serum p-tau217 across various platforms. This multi-faceted approach ensures a robust examination of p-tau217 as a potential biomarker for AD.

Limitations of this study include the following. Firstly, the sample size across cohorts was relatively small, particularly for the NULISA assay, where only one cohort with a reduced sample size was processed. This limitation may affect the generalizability of our results. Future evaluations utilizing a larger scale and ideally in real-world settings will be needed to confirm our findings. Furthermore, the HCP cohort contained limited numbers of Aβ PET-positive patients. Further validation using a larger cohort with a substantial number of Aβ PET-positive individuals will be necessary.

Conclusion

In conclusion, we evaluated serum p-tau217 using four assays—ALZpath, Pittsburgh, Lumipulse, and NULISA—and compared the results with plasma p-tau217 levels in matched samples. Significant correlations between plasma and serum p-tau217 were observed within all assays. Both plasma and serum p-tau217 showed strong AD diagnostic performance across the assays, with some variation in measured levels. This study offers comprehensive insights into serum p-tau217 and its measurement, supporting its potential integration into diverse clinical

settings for earlier detection and management of AD. Additionally, it provides insights into assay-to-assay differences in performance, aiding in the selection of appropriate assays for clinical and research applications. Future research with larger sample sizes and further exploration of different matrices and assay types will be crucial to optimizing its clinical application.

Non-standard abbreviations

AD, Alzheimer disease; p-tau, phosphorylated tau; EDTA, ethylenediaminetetraacetic acid; AUC, area under the curve; PET, positron emission tomography; CSF, cerebrospinal fluid; p-tau217, phosphorylated tau217; Aβ, amyloid-beta; NULISA, nucleic acid linked immuno-sandwich assay; Pitt-ADRC, University of Pittsburgh Alzheimer's Disease Research Center; MoCA, Montreal Cognitive Assessment; MMSE, Mini-Mental State Examination; CDR, Clinical Dementia Rating; HCP, Human Connectome Project; PiB, Pittsburgh Compound B; MRI, magnetic resonance imaging; Simoa, single molecule array; IQR, interquartile range; ROC, receiver operating characteristic; NPQ, NULISA Protein Quantification; 2^NPQ, log2 transformation; GED, general educational development; LLOQ, lower limit of quantification.

Author contributions

The corresponding author takes full responsibility that all authors on this publication have met the following required criteria of eligibility for authorship: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; (c) final approval of the published article; and (d) agreement to be accountable for all aspects of the article thus ensuring that questions related to the accuracy or integrity of any part of the article are appropriately investigated and resolved. Nobody who qualifies for authorship has been omitted from the list.

Research funding

The Pittsburgh ADRC and the HCP study were funded by NIH/NIA grants P30AG066468 and R01AG072641 respectively. TKK and the Karikari Laboratory were supported by the NIH/NIA grants R01AG083874, U24AG082930 and P01AG025204, and a professorial endowment from the Department of Psychiatry, University of Pittsburgh.

Disclosures

TKK has consulted for Quanterix Corp., has received honoraria from the NIH for study section membership, and honoraria for speaker/grant review engagements from UPENN, UW-Madison, Advent Health, Brain Health conference, Barcelona-Pittsburgh conference and CQDM Canada, all outside of the submitted work. TKK has received blood biomarker data on defined research cohorts from Janssen and Alamar Biosciences for independent analysis and publication, with no financial incentive and/or research funding included. TKK is an inventor on patent *#WO2020193500A1* and patent applications *#2450702-2, #63/693,956, #63/679,361,* and *63/672,952*. YC and XZ are listed inventors on the University of Pittsburgh provisional patent *#63/672,952*. The other authors report no conflict of interest.

Role of sponsor

The funding organizations played no role in the design of study, choice of enrolled patients, review and interpretation of data, preparation of manuscript, or final approval of manuscript.

Acknowledgements

We thank the Pittsburgh ADRC and HCP study participants and their families and caregivers.

Reference

1. Blennow, K., et al., Amyloid biomarkers in Alzheimer's disease. Trends in pharmacological sciences, 2015. 36(5): p. 297-309.

2. Dubois, B., et al., Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement, 2016. 12(3): p. 292-323.

3. Wang, M.J., et al., Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease. Alzheimer's Research & Therapy, 2017. 9(1): p. 98.

4. Keshavan, A., et al., Population-based blood screening for preclinical Alzheimer's disease in a British birth cohort at age 70. Brain : a journal of neurology, 2021. 144(2): p. 434-449.

5. Olvera-Rojas, M., et al., Influence of medical conditions on the diagnostic accuracy of plasma p-tau217 and p-tau217/Aβ42. Alzheimer's & Dementia, 2024.

6. Jack, C.R., et al., Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimer's & Dementia, 2024. 20(8): p. 5143-5169.

7. Dubois, B., et al., Alzheimer Disease as a Clinical-Biological Construct—An International Working Group Recommendation. JAMA Neurology, 2024.

8. Palmqvist, S., et al., Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. Jama, 2020. 324(8): p. 772-781.

9. Gonzalez-Ortiz, F., et al., A novel ultrasensitive assay for plasma p-tau217: Performance in individuals with subjective cognitive decline and early Alzheimer's disease. Alzheimer's & Dementia, 2024. 20(2): p. 1239-1249.

10.	Therriault, J., et al., Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability. Nat Aging, 2024. 4(11): p. 1529-1537.

11.	Gildengers, A., et al., Where Do Plasma Biomarkers fit in With Current Alzheimer's Disease Detection? Am J Geriatr Psychiatry, 2024.

12.	Therriault, J., et al., Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease. Alzheimers Dement, 2023. 19(11): p. 4967-4977.

13.	Milà-Alomà, M., et al., Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer's disease. Nat Med, 2022. 28(9): p. 1797-1801.

14.	Mattsson-Carlgren, N., et al., Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Molecular Medicine, 2021. 13(6): p. e14022.

15.	Ferreira, P.C.L., et al., Plasma p-tau231 and p-tau217 inform on tau tangles aggregation in cognitively impaired individuals. Alzheimers Dement, 2023. 19(10): p. 4463-4474.

16.	Karikari, T.K., et al., Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. Nature Reviews Neurology, 2022. 18(7): p. 400-418.

17.	Kennedy, A.D., et al., Global biochemical analysis of plasma, serum and whole blood collected using various anticoagulant additives. PLOS ONE, 2021. 16(4): p. e0249797.

18.	Lopez, O.L., et al., Research evaluation and diagnosis of probable Alzheimer's disease over the last two decades: I. Neurology, 2000. 55(12): p. 1854-1862.

19.	Lopez, O.L., et al., Research evaluation and diagnosis of possible Alzheimer's disease over the last two decades: II. Neurology, 2000. 55(12): p. 1863-9.

20.	Cohen, A.D., et al., Connectomics in Brain Aging and Dementia – The Background and Design of a Study of a Connectome Related to Human Disease. Frontiers in Aging Neuroscience, 2021. 13.

21.	Zeng, X., et al., Alzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting. Molecular Neurodegeneration, 2024. 19(1).

22.	Sehrawat, A., et al., Plasma p-tau217: accuracies for autosomal dominant and sporadic Alzheimer's disease in the community. Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2024. Under review.

23.	Sehrawat, A., et al. Technical and clinical validation of a novel plasma p-tau217 assay: evaluation in real world population-based and racially-diverse cohorts. in Alzheimer's Association International Conference. 2024. ALZ.

24.   Zeng, X., et al., Multi-analyte proteomic analysis identifies blood-based neuroinflammation, cerebrovascular and synaptic biomarkers in preclinical Alzheimer's disease. Molecular Neurodegeneration, 2024. 19(1).

25.   Ashton, N.J., et al., Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology. JAMA Neurology, 2024. 81(3): p. 255-263.

26.   Warmenhoven, N., et al., A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests. Brain, 2024.

27.   Ashton, N.J., et al., Effects of pre‑analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2021. 13(1): p. e12168.

28.   Rózga, M., et al., Preanalytical sample handling recommendations for Alzheimer's disease plasma biomarkers. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2019. 11: p. 291-300.

29.   Verberk, I.M.W., et al., Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease–related blood-based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group. Alzheimer's & Dementia, 2022. 18(8): p. 1484-1497.

30.   Kac, P.R., et al., Diagnostic value of serum versus plasma phospho-tau for Alzheimer's disease. Alzheimer's Research & Therapy, 2022. 14(1).

Figure Legend

Figure 1: Comparison of p-tau217 levels between matched plasma and serum samples in the Pitt-ADRC cohort for three assays: ALZpath, Pittsburgh, and Lumipulse. A. Boxplots distribution of p-tau217 concentrations. The center line of each box represents the median, the edges are the 25th and 75th percentile, and the whiskers extend to the furthest non-outlier data value (1.5x IQR away from the 25th and 75th percentiles). **B**. Scatter plot distributions with lines connecting matched plasma and serum samples from the same individual. P values indicate the significance of the difference between plasma and serum according to the Wilcoxon signed rank test in concentrations. **C.** Correlation plots between plasma and serum concentrations. Correlation coefficients and associated p values were based on Spearman correlation. Lines represent the linear regression line. N= 50 for the Pitt-ADRC cohort across all assays.

Figure 2: Comparison of p-tau217 biomarker concentrations between matched plasma and serum samples in the HCP cohort for three assays: ALZpath, Pittsburgh, and Lumipulse. **A.** Boxplots depicting the distribution of p-tau217 concentrations in plasma and serum for the three assays. The center line of each box represents the median, the edges are the 25th and 75th percentile, and the whiskers extend to the furthest non-outlier data value (1.5x IQR away from the 25th and 75th percentiles). **B.** Scatter plots with lines connecting plasma and serum samples from the same individual. P values were according to the Wilcoxon signed rank test. **C.** Correlation plots between plasma and serum concentrations for each assay Correlation coefficients and associated p values were based on Spearman correlation. Lines represent the linear regression lines. N=34 for Lumipulse and n=33 for Pittsburgh and ALZPath.

Figure 3: Comparison of p-tau217 concentration values between matched plasma and serum samples measured with the NULISA assay. A. Boxplots depicting the distribution of inversed log2 NULISA Protein Quantification (2^NPQ) values in plasma vs. serum. The center line of each box represents the median, the edges are the 25th and 75th percentile, and the whiskers extend to the furthest non-outlier data value (1.5x IQR away from the 25th and 75th percentiles). **B.** Individual NPQ values for matched plasma and serum are connected by lines to illustrate paired comparisons for identical participants. **C.** Correlation plots between plasma and serum NPQ values for each assay analyzed using Spearman correlation. P-values indicating statistical significance ($p < 0.0001$). N=43 for the NULISA using Pitt-ADRC reduced cohort.

Figure 4: The boxplots illustrate the clinical performance of p-tau217 in matched plasma and serum samples for the Pitt-ADRC cohort (according to clinical diagnosis; A) and the HCP cohort (by Aβ PET status; B). The center line of each box represents the median, the edges are the 25th and 75th percentile, and the whiskers extend to the furthest non-outlier data value (1.5x IQR away from the 25th and 75th percentiles). The p-values were calculated using Wilcoxon rank sum test for the Pitt-ADRC cohort. Due to having only three cases in the Aβ PET positive sample size, no statistical analysis was performed for the HCP cohort. The normal control (Normal) and Probable AD (AD) were assessed through clinical assessment. The Negative and Positive were assessed based on Aβ PET imaging result.

Figure 5: Performance of serum vs. plasma p-tau217 to differentiate individuals with probable AD from normal controls in the Pitt-ADRC cohort. The figure illustrates the AUC and 95% confidence interval of the assays. "P" represents plasma and "S" represents serum. Calculations of the AUC were based solely on the Pitt-ADRC cohort (n=50). The NULISA assays were conducted using the same cohort but with a reduced number of samples (n=43).

Table 1. Demographic and clinical characteristics of the Pitt-ADRC and Human Connectome Project cohorts.

Pitt-ADRC Cohort	Overall	Normal control	Probable AD	p-value
Overall	50	34	16	
Sex (%)				
Male	29 (58.0)	20 (58.8)	9 (56.2)	1.000
Female	21 (42.0)	14 (41.2)	7 (43.8)	
CDR (%)				
0	16 (32.0)	16 (47.1)	0 (0.0)	<0.001
0.5	24 (48.0)	16 (47.1)	8 (50.0)	
1	5 (10.0)	0 (0.0)	5 (31.2)	
2	5 (10.0)	2 (5.9)	3 (18.8)	
Age in years (IQR)	76.0 [70.3, 82.0]	77.0 [70.3, 82.0]	75.5 [70.8, 78.3]	0.811
MMSE (IQR)	27.0 [23.0, 29.0]	28.0 [27.0, 29.0]	21.5 [18.5, 23.3]	<0.001
MoCA (IQR)	23.0 [16.5, 27.0]	27.0 [23.0, 28.0]	16.0 [14.0, 19.3]	<0.001

Pitt-ADRC sub-cohort for NULISA	Overall	Normal control	Probable AD	p-value
Overall	43	29	14	
Sex (%)				
Male	25 (58.1)	17 (58.6)	8 (57.1)	1.000
Female	18 (41.9)	12 (41.4)	6 (42.9)	
CDR (%)				
0	15 (34.9)	15 (51.7)	0 (0.0)	0.001
0.5	19 (44.2)	12 (41.4)	7 (50.0)	
1	4 (9.3)	0 (0.0)	4 (28.6)	
2	5 (11.6)	2 (6.9)	3 (21.4)	
Age in years (IQR)	76.0 [70.0, 81.5]	77.0 [70.0, 82.0]	75.5 [70.3, 76.8]	0.755
MMSE (IQR)	27.0 [23.0, 29.0]	29.0 [27.0, 29.0]	22.0 [19.3, 23.8]	<0.001
MoCA (IQR)	25.0 [17.0, 28.0]	27.0 [25.0, 29.0]	15.5 [14.0, 19.8]	<0.001

HCP Cohort	Overall	Aβ PET-Negative	Aβ PET-Positive	p-value *
Overall	34	31	3	
Sex (%)				
Male	10 (29.4)	9 (29.0)	1 (33.3)	
Female	24 (70.6)	22 (71.0)	2 (66.7)	
Race (%)				
White	22 (68.8)	19 (65.5)	3 (100.0)	
Black/African American	9 (28.1)	9 (31.0)	0 (0.0)	

Native American, Irish, Southern Asian	1 (3.1)	1 (3.4)	0 (0.0)
Education (%)			
Less than eighth grade	12 (35.3)	11 (35.5)	1 (33.3)
Eighth to eleventh grade	5 (14.7)	5 (16.1)	0 (0.0)
Graduated high school or GED	16 (47.1)	14 (45.2)	2 (66.7)
Certificate	1 (2.9)	1 (3.2)	0 (0.0)
Age in years (IQR)	65.0 [62.3, 74.0]	65.0 [61.5, 73.5]	74.0 [73.0, 78.5]
MoCA (IQR)	25.5 [23.3, 27.8]	25.0 [23.0, 28.0]	26.0 [25.5, 26.5]

Median and IQR values are reported for continuous variables. Frequencies and percentages are shown for categorical variables.

P-values were calculated using Wilcoxon rank-sum test for continuous variables and Fisher's exact test for categorical variables, respectively, between the two test groups in each cohort.

*For the HCP cohort, statistical comparison between the Aβ-PET positive and -negative groups was not done given the small sample size for the Aβ-PET positives (only three cases).

Abbreviations: CDR, Clinical Dementia Rating; MMSE, Mini Mental State Examination; MoCA, Montreal Cognitive Assessment.

Figure 1

Pitt-ADRC Cohort

Figure 2

HCP Cohort

Figure 3

NULISA

Figure 4

A — Pitt-ADRC Cohort

B — HCP Cohort

Figure 5